Search Results

Shares of Kaleido Biosciences are plunging after the company announced its intentions to cease all company operations, lay off its remaining staff and delist from the Nasdaq Exchange.

Kaleido Biosciences, Inc. today reported financial results for the third quarter ended September 30, 2021.

Kaleido Biosciences, Inc. today reported financial results for the second quarter ended June 30, 2021.

Kaleido Biosciences, Inc. today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021.

Kaleido Biosciences, Inc. today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.

Kaleido Biosciences, Inc. today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

Kaleido Biosciences, Inc. today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”).

Kaleido Biosciences, Inc. today announced that CFO William Duke will participate in a fireside chat at the Canaccord Genuity Growth Conference at 2:30PM ET on Thursday, August 12.

Kaleido Biosciences, Inc., a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, announced that CEO Dan Menichella will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.